Remedy Robotics announced that it entered a strategic partnership with the Society of Vascular and Interventional Neurology’s Mission Thrombectomy.
Mission Thrombectomy is a leading clinician network dedicated to accelerating access to endovascular thrombectomy in stroke. The partnership would expand access to thrombectomy in the U.S. and globally using the Remedy Robotics N1 system. This marks the second such partnership for the company in recent weeks after a deal with the Australian Stroke Alliance.
San Francisco-based Remedy Robotics unveiled the N1 system earlier this month. The company touts N1 as the world’s first remotely operable endovascular robot. It combines proprietary hardware and AI-enabled software to enable faster, safer and more effective innovation in cardiovascular conditions. Those include stroke, heart attack or vascular trauma, whether across the room or across the globe.
Remedy Robotics could square up with the likes of Microbot Medical and Stereotaxis in the endovascular robotics space.
Through this partnership, Remedy becomes Mission Thrombectomy’s exclusive robotics partner. The company plans to work in close collaboration with Mission’s world-leading clinical network across more than 100 countries. They hope to test, develop and guide the global rollout of Remedy’s telerobotic technology into stroke-thrombectomy workflows.
“We are thrilled that Mission Thrombectomy has selected Remedy Robotics as its exclusive robotics partner to expand access to endovascular thrombectomy for stroke patients both in the U.S. and worldwide,” said Dr. David Bell, CEO and co-founder of Remedy Robotics.“This collaboration will advance our shared vision of making the best endovascular intervention available to patients, wherever they are. Working with Mission Thrombectomy’s world-class clinicians and global network, we will make endovascular thrombectomy safer and more equitably accessible to patients across the U.S. and the world.”
